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PregabalinNeuropathic pain is a debilitating condition that is often resistant to common analgesics, such as opioids, but is
sensitive to some antidepressants, an effect that seems to bemediated by spinal cord 5-HT3 receptors. Because
the analgesic potential of monoamine oxidase-A (MAO-A) inhibitors is understudied, we evaluated the poten-
tial antinociceptive effect of the reversible MAO-A inhibitors moclobemide and 2-(3,4-dimethoxy-phenyl)-
4,5-dihydro-1H-imidazole (2-DMPI) in amouse neuropathic painmodel induced by chronic constriction inju-
ry (CCI) of the sciatic nerve. Neuropathic mice showed a decreased mechanical paw withdrawal threshold
(PWT) 7 days after lesion compared with the baseline PWT, characterizing the development of hyperalgesia.
Moclobemide (100–300 μmol/kg, s.c.) and 2-DMPI (30–300 μmol/kg, s.c.) treatments were able to reverse the
CCI-induced hyperalgesia, with 50% inhibitory dose (ID50) values of 39 (18–84) and 11 (4–33) μmol/kg, and
maximum inhibition (Imax) values of 88±14 and 98±15%, respectively, at the 300 μmol/kg dose. In addition,
we observed a signiﬁcant increase in the MAO-A activity in the lumbar spinal cord of CCI-submitted mice
compared with sham-operated animals. Furthermore, the antihyperalgesic effects of both 2-DMPI and
moclobemide were largely reversed by intrathecal injection of the 5-HT3 receptor antagonist ondansetron
(10 μg/site). These results suggest a possible involvement of MAO-A in the mechanisms of neuropathic pain
and a potential utility of the reversible inhibitors ofMAO-A in the development of new therapeutic approaches
to treat it.
© 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Neuropathic pain is a pathological condition that frequently results
from a lesion or disease of the somatosensory nervous system (Treede
et al., 2008). Common complaints of neuropathic pain patients are
spontaneous pain and painful hypersensitivity to mechanical, thermal
and/or chemical noxious (hyperalgesia) or innocuous (allodynia)
stimuli (Costigan et al., 2009). The management of neuropathic
pain is still a major challenge to clinicians because it is unresponsive
to most of the currently used analgesic drugs (Dworkin et al., 2007;chronic constriction injury;
idazole; GABA, γ-amino bu-
tryptamine; ID50, 50% inhibi-
onoamine oxidase-A; MAO-B,
T, paw withdrawal threshold.
ão em Farmacologia, Centro de
a, 97105-900, Santa Maria, RS,
.
vier OA license.Woolf and Mannion, 1999). In this regard, some antidepressants
represent useful tools in neuropathic pain treatment (Sindrup et al.,
2005). In fact, tricyclic antidepressants, together with anticonvulsants,
are considered to be ﬁrst-line drugs for the treatment of neuropathic
pain (Micó et al., 2006).
Although antidepressants have been used for the treatment of
chronic pain conditions for decades, the mechanism of this action is
still unclear. Many believe that the increased availability of serotonin
(5-hydroxytryptamine, 5-HT) and noradrenaline in the synaptic cleft
is the main mechanism of the analgesic action of antidepressants
(Micó et al., 2006). Furthermore, 5-HT3 receptor activation has been
implicated in the antinociceptive effect of spinal serotonin by increasing
the activity of the descending inhibitory pathways (Bardin et al., 2000),
which may be compromised in chronic pain conditions (Ardid et al.,
1995).
Similar to tricyclic antidepressants, monoamine oxidase (MAO)
inhibitors also increase the availability of monoamines in the central
nervous system (Youdim et al., 2006). Although some authors have
shown the analgesic properties of reversible MAO-A inhibitors, such
as moclobemide, in the treatment of nociceptive and psychogenic
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there are only a few preliminary studies evaluating the therapeutic
potential of these drugs for neuropathic pain and their results are
controversial (Apaydin et al., 2001; Menkes et al., 1995).
Because neuropathic pain is a debilitating condition of difﬁcult
treatment and antidepressants have long been used for the treatment
of this type of pain (Sindrup et al., 2005), the aims of this study were
to conﬁrm the antinociceptive potential of the reversible MAO-A in-
hibitor moclobemide and evaluate the effect of 2-(3,4-dimethoxy-
phenyl)-4,5-dihydro-1H-imidazole (2-DPMI), a novel reversible and
preferential MAO-A inhibitor with antidepressant properties (Villarinho
et al., 2012a), in a mouse neuropathic pain model. We also investigated
possible changes in monoamine oxidase activity in neuropathic mice, as
well as the involvement of spinal 5-HT3 receptors in the antinociceptive
effect of reversible MAO-A inhibitors.
2. Materials and methods
2.1. Animals
Experiments were conducted using male Swiss mice (25–30 g)
from our own colony. Mice were maintained in polycarbonate cages
with free access to food and water on a 12 h alternating light–dark
schedule in a temperature-controlled (22±3 °C) room. Mice were
kept and used in accordance with the guidelines of the National
Council for Control of Animal Experiments (CONCEA) and the National
Institutes of Health Guide for the Care and Use of Laboratory Animals.
All experiments pertaining to this study were approved by the Ethics
Committee of the Federal University of Santa Maria (process number
64/2011). The number of animals and intensity of the noxious stimuli
used were the minimum necessary to demonstrate the consistent effects
of drug treatments. For behavioral tests, drugs were administered in a
random order and the behavioral measure was carried out by a blinded
investigator. Animalswere allowed to adapt to the test environment for
2 h before testing.
2.2. Drugs
The synthesis of 2-DMPI was carried out by the previously reported
method of condensation involving 3,4-dimethoxybenzaldehyde and
ethylenediamine in the presence of N-bromosuccinimide under ultra-
sound irradiation (Sant'Anna et al., 2009). Analysis of 1H and 13C nuclear
magnetic resonance spectra showed analytical and spectroscopic data
in full agreement with the assigned structure. Moclobemide (Aurorix®,
Roche, Brazil) and2-DMPIwere dissolved in a vehicle solution (5%Tween
80, 20% polyethyleneglycol and 75% saline) and pregabalin (Lyrica®,
Pﬁzer, Brazil) was dissolved in sterile saline. Moclobemide, 2-DMPI and
pregabalin were administered to mice by the subcutaneous (s.c.) route,
while ondansetron (Nausedron®, Cristália, Brazil) was intrathecally
(i.t.) injected in a volume of 5 μL, according to the technique de-
scribed by Hylden and Wilcox (1980). Kynuramine dihydrobromide
and selegiline hydrochloride were purchased from Sigma Chemical
Co. (St. Louis, USA) and dissolved in incubation buffer. All other re-
agents were of analytical grade and were purchased from local
suppliers.
2.3. Measurement of mechanical hyperalgesia
In this study, we used mechanical hyperalgesia as a parameter of
nociception, whichwas characterized by a signiﬁcant decrease in theme-
chanical paw withdrawal threshold (PWT). The measurement of me-
chanical PWT was carried out using the up-and-down paradigm as
previously described by Chaplan et al. (1994) for rats and adapted by
Villarinho et al. (2012b) for mice. Brieﬂy, mice were ﬁrst acclimatized in
individual clear Plexiglas boxes (9×7×11 cm) on an elevated wire
mesh platform to allow the access to the plantar surface of the righthind paw. Seven calibrated von Frey ﬁlaments of increasing stiffness
(0.02, 0.07, 0.16, 0.4, 1.4, 4, and 10 g) were chosen. Testing was initiated
with the 0.4 g hair, and each hair was applied perpendicularly to the
plantar surface of the right hind paw, with sufﬁcient force to bend the ﬁl-
ament, for about 5 s. Lifting of the paw indicated a positive response and
prompted the use of the next weaker (i.e. lighter) ﬁlament. Absence of a
paw withdrawal response prompted the use of the next stronger (i.e.
heavier) ﬁlament. This paradigm continued until a total of six measure-
ments or until four consecutive positive or four consecutive negative re-
sponses occurred. All measurements were carried out in the paw
ipsilateral to the surgical or sham procedure, and the 50% mechanical
PWT response was calculated from the resulting scores as previously
described by Dixon (1980). The 50% PWT was expressed in grams (g)
and was evaluated before (baseline) and several times after treatments
or surgical procedures.2.4. Neuropathic pain model
For induction of chronic mononeuropathy, mice were ﬁrst anesthe-
tized by intraperitoneal injection of 90 mg/kg of ketamine plus 3 mg/kg
of xylazine hydrochloride. Neuropathy was induced by chronic con-
striction injury (CCI) of the sciatic nerve using a similar procedure to
that previously described by Bennett and Xie (1988) for rats and
adapted by Sommer et al. (1998) formice. Three loosely constrictive lig-
atures were placed around the right sciatic nerve under anesthesia. In
sham surgeries, animals were anesthetized and the sciatic nerve was
exposed without performing constriction. Sham-operated animals were
used as controls.
Seven days after the procedures (sham or CCI), the nociception test
was carried out at time 0 (before drug injection). Then,micewere treated
with 2-DMPI (300 μmol/kg, s.c.), moclobemide (300 μmol/kg, s.c.),
vehicle (10 mL/kg, s.c.), pregabalin (100 μmol/kg, s.c.), or saline
(10 mL/kg, s.c.), and mechanical sensitivity was measured 1, 2, 4, 6,
and 24 h after treatment (time-course curve). For the dose–response
curve, CCI-submitted animals received a single injection of 2-DMPI (3,
30, or 300 μmol/kg, s.c.), moclobemide (30, 100, or 300 μmol/kg, s.c.),
or vehicle 2 h before the nociceptive test. To assess the involvement of
the serotonergic system in the antinociceptive effect of reversible
MAO-A inhibitors, mice received an intrathecal injection of the 5-HT3
receptor antagonist ondansetron (10 μg/site) or phosphate buffered
saline (PBS; 5 μL/site), 30 min before the peak effect of the drugs
(90 min after subcutaneous injection of 2-DMPI or moclobemide).
The mechanical paw withdrawal threshold was measured 30 min
later. The dose of ondansetron was selected based on the results of
a previous study (Dogrul et al., 2012).2.5. Determination of MAO-A activity
For MAO-A activity measurement, mice submitted to surgical pro-
cedure (sham or CCI) were killed 7 days after the surgical procedure
and different central nervous system structures (lumbar spinal cord,
cerebral cortex, and striatum) were collected and homogenized in
assay buffer (16.8 mM Na2HPO4, 10.6 mM KH2PO4, and 3.6 mM KCl,
pH 7.4). The entire lumbar spinal cord (L1 to L6) was dissected by
mechanical extrusion. The MAO-A activity was measured by a ﬂuoro-
metric method that detects the formation of the ﬂuorescent product
4-hydroxyquinoline (4-HQ) from kynuramine, as previously de-
scribed (Matsumoto et al., 1985; Villarinho et al., 2012b). Brieﬂy,
assays were performed in a reaction mix containing assay buffer,
tissue homogenates of central nervous system structures (0.25 mg of
protein), the selective monoamine oxidase-B (MAO-B) inhibitor
selegiline (250 nM), and kynuramine (100 μM) and were incubated
at 37 °C for 30 min. The results were expressed as nmol of 4-HQ/
min/mg of protein.
Fig. 1. Effect ofmoclobemide treatment on themechanical nociceptive threshold in amouse
neuropathic pain model. (A) Time–course curve of the pawwithdrawal threshold (PWT) in
sham-operated mice treated with moclobemide (300 μmol/kg, s.c.) or vehicle (n=7 per
group). (B) Time–course curve of the PWT in chronic constriction injury (CCI)-submitted
mice treated with moclobemide (300 μmol/kg, s.c.) or vehicle (n=7 per group).
***Pb0.001 compared with the baseline PWT (one-way ANOVA with repeated measures
followed by the Student–Newman–Keuls test); ###Pb0.001 compared with the respective
control group (two-way ANOVA with repeated measures followed by Bonferroni's test).
(C) Dose–response curve of PWT in CCI-submitted mice treated with moclobemide (30,
100 or 300 μmol/kg, s.c.) or vehicle (n=6–7 per group). ⁎⁎⁎Pb0.001 compared with the re-
spective PWTbefore CCI; ###Pb0.001 comparedwith the respective PWT after CCI (two-way
ANOVA with repeated measures followed by Bonferroni's test). Data are expressed as the
means±S.E.M.
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Motor coordination was evaluated using the rota-rod test (Godoy
et al., 2004). The apparatus consisted of a bar (3.7 cm in diameter)
divided into 3 separate compartments, placed at a 25 cm height
and rotating at a ﬁxed velocity of 8 rpm. Twenty-four hours before
testing, all animals were submitted to a training session until they
could remain in the apparatus for 60 s without falling. On the test
day, mice received a single injection of moclobemide (300 μmol/kg,
s.c., 2 h before test), 2-DMPI (300 μmol/kg, s.c., 2 h before test), vehicle
(10 mL/kg, s.c., 2 h before test), pregabalin (100 μmol/kg, s.c., 1 h
before test), or saline (10 mL/kg, s.c., 1 h before test). During the
test session, the latency (in seconds) for the ﬁrst fall and the total
number of fall during a 4 min period were measured.
2.7. Statistical analyses
The results were expressed as the means±S.E.M., except for the
ID50 values (i.e., the drug dose that reduces nociceptive responses
by 50% relative to the control value), which were expressed as geo-
metric means accompanied by their respective 95% conﬁdence limits,
and the latency for the ﬁrst fall and the fall number (rota-rod test),
which were represented as medians followed by their 25th and 75th
percentiles. ID50 values were determined by non-linear regression
using a sigmoidal dose–response with a variable slope equation. The
percentages of maximum inhibition (Imax) were calculated for the
maximal developed responses in comparison with vehicle-treated
animals. Statistical analyses were carried out using GraphPad Prism
5.0 software. Differences among groups were evaluated with an un-
paired t-test, one-way analysis of variance (ANOVA) followed by
the Student–Newman–Keuls test, or two-way ANOVA followed by
Bonferroni's test, as appropriate. Reported F values were obtained
from two-way ANOVA analysis and indicate the interaction between
time and treatment factors. Differences were considered signiﬁcant
when Pb0.05.
3. Results
3.1. Effects of reversible MAO-A inhibitors and pregabalin on CCI-induced
hyperalgesia
Mechanical nociceptive thresholds were stable before and after the
sham procedure in both vehicle and moclobemide (300 μmol/kg,
s.c.)-treated mice (Fig. 1A; F(6,72)=0.56, P=0.763). On the other
hand, CCI of the sciatic nerve decreased the mean PWT of the
ipsilateral hind paw by approximately 85% seven days after lesion
(time 0) compared with the mean baseline PWT (1.30±0.11 g before
CCI and 0.20±0.02 g after CCI). The hyperalgesia produced by CCI
was maintained throughout the experiment in vehicle-treated mice,
but it was reversed by moclobemide (300 μmol/kg, s.c.) from 1 to
4 h after treatment (Fig. 1B; F(6,72)=13.55, Pb0.001). Moclobemide
also presented an antinociceptive effect at 100 μmol/kg, but not at
30 μmol/kg (Fig. 1C; F(6,46)=4.87, Pb0.001), with an ID50 value of
39 (18–84) μmol/kg and an Imax value of 81±10%.
The paw withdrawal threshold of sham-operated animals treated
with 2-DMPI (300 μmol/kg, s.c.) was not signiﬁcantly different from
vehicle-treated mice (Fig. 2A; F(6,60)=0.16, P=0.987). However, the
administration of 2-DMPI (300 μmol/kg, s.c.) in the CCI-submitted
mice produced an antihyperalgesic effect from 1 to 6 h after treatment
(Fig. 2B; F(6,72)=7.36, Pb0.001). An antinociceptive effect was also
observed 2 h after treatment with 2-DMPI at 30 μmol/kg, but not at
3 μmol/kg (Fig. 2C; F(6,54)=3.87, Pb0.01), with values of ID50 and
Imax of 11 (4–33) μmol/kg and 99±12%, respectively.
For comparative purposes,we also tested the effect of the alpha2-delta
(α2-δ) ligand pregabalin in the CCI model. Pregabalin (100 μmol/kg, s.c.)
caused no change in mechanical nociceptive thresholds of sham-operated animals compared with saline-treated mice (Fig. 3A;
F(6,66)=0.75, P=0.609). Nevertheless, the CCI-induced hyperalgesia
was reversed by pregabalin (100 μmol/kg, s.c.) from 1 to 2 h after treat-
ment (Fig. 3B; F(6,72)=5.50, Pb0.001).
3.2. Ex vivo MAO-A activity in sham-operated or CCI-submitted mice
A signiﬁcant increase inMAO-A activity was observed in the lumbar
spinal cord of CCI-submitted mice compared with sham-operated
Fig. 2. Effect of 2-DMPI treatment on the mechanical nociceptive threshold in a mouse
neuropathic pain model. (A) Time–course curve of the paw withdrawal threshold (PWT)
in sham-operated mice treated with 2-DMPI (300 μmol/kg, s.c.) or vehicle (n=6 per
group). (B) Time–course curve of the PWT in chronic constriction injury (CCI)-submitted
mice treated with 2-DMPI (300 μmol/kg, s.c.) or vehicle (n=7 per group). ***Pb0.001
compared with the baseline PWT (one-way ANOVA with repeated measures followed
by the Student–Newman–Keuls test); #Pb0.05, ##Pb0.01 or ###Pb0.001 compared with
the respective control group (two-way ANOVA with repeated measures followed by
Bonferroni's test). (C) Dose–response curve of the PWT in CCI-submitted mice treated
with 2-DMPI (3, 30 or 300 μmol/kg, s.c.) or vehicle (n=7–8 per group). ⁎⁎⁎Pb0.001
compared with the respective PWT before CCI; ##Pb0.01 or ###Pb0.001 compared with
the respective PWT after CCI (two-way ANOVA with repeated measures followed by
Bonferroni's test). Data are expressed as the means±S.E.M.
Fig. 3. Effect of pregabalin treatment on the mechanical nociceptive threshold in a
mouse neuropathic pain model. (A) Time–course curve of the pawwithdrawal threshold
(PWT) in sham-operated mice treated with pregabalin (100 μmol/kg, s.c.) or saline
(n=6–7 per group). (B) Time–course curve of the PWT in chronic constriction injury
(CCI)-submitted mice treated with pregabalin (100 μmol/kg, s.c.) or saline (n=7 per
group). ***Pb0.001 compared with the baseline PWT (one-way ANOVA with repeated
measures followed by the Student–Newman–Keuls test); #Pb0.05 or ###Pb0.001 com-
pared with the respective control group (two-way ANOVA with repeated measures
followed by Bonferroni's test). Data are expressed as the means±S.E.M.
Fig. 4.Monoamine oxidase-A (MAO-A) activity in the lumbar spinal cord, striatum and
cerebral cortex of sham-operated or chronic constriction injury (CCI)-submitted mice
(n=6–8 per group). *Pb0.05 compared with sham-operated mice (unpaired t-test).
Data are expressed as the means±S.E.M.
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cerebral cortex or the striatum (Fig. 4).
3.3. Effect of intrathecal administration of a 5-HT3 receptor antagonist on
the antihyperalgesic effect of reversible MAO-A inhibitors
Intrathecal administration of ondansetron (10 μg/site; 90 min
after subcutaneous injection of vehicle, 2-DMPI, or moclobemide), a5-HT3 receptor antagonist, largely reversed the antihyperalgesic effect
of the reversible MAO-A inhibitors moclobemide (300 μmol/kg, s.c.;
F(1,24)=13.93, Pb0.01) and 2-DMPI (300 μmol/kg, s.c.; F(1,28)=9.62,
Pb0.01) (Fig. 5). Furthermore, ondansetron (10 μg/site, i.t.) did not
change the mechanical hyperalgesia induced by CCI in mice treated
subcutaneously with vehicle (F(1,26)=0.04, P=0.849) (Fig. 5).
Fig. 5. Effects of intrathecal treatment with the 5-HT3 receptor antagonist ondansetron
(10 μg/site; 90 min after s.c. treatment) or phosphate buffered saline (PBS) on the
antihyperalgesic effect of the reversible MAO-A inhibitors moclobemide (300 μmol/kg)
and 2-DMPI (300 μmol/kg), administered subcutaneously 2 h before the mechanical
paw withdrawal threshold (PWT) measurement, in chronic constriction injury
(CCI)-submitted mice (n=7–8 per group). ⁎⁎⁎Pb0.001 compared with the respective
PWT before CCI; ###Pb0.001 compared with the respective PWT after CCI (two-way
ANOVA with repeated measures followed by Bonferroni's test). Data are expressed as
the means±S.E.M.
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The motor coordination of mice was not changed by the treatment
with moclobemide (300 μmol/kg, s.c.) or 2-DMPI (300 μmol/kg, s.c.)
2 h before test comparedwith the vehicle-treated animals, as evaluated
by both the latency (s) for the ﬁrst fall and the total fall number in the
rota-rod test (Table 1). Moreover, the administration of pregabalin
(100 μmol/kg, s.c.) 1 h before test also caused no change in the motor
coordination compared with the saline-treated animals (Table 1).
4. Discussion
Neuropathic pain is triggered by lesions to the somatosensory
nervous system that alter its structure and function so that pain occurs
spontaneously and responses to noxious and innocuous stimuli are
pathologically ampliﬁed (Costigan et al., 2009). The treatment of neuro-
pathic pain is challenging, in part because of its multiple etiologies,
symptoms and underlying mechanisms (Bridges et al., 2001; Stacey,
2005). Antidepressants have been successfully used for the treatment
of this type of chronic pain (Sindrup et al., 2005).
In this study, we evaluated the potential antinociceptive action of
two antidepressants, the reversible MAO-A inhibitors moclobemide
and 2-DMPI, in a mouse model of neuropathic pain. Both moclobemide
and 2-DMPI presented a long-lasting and efﬁcacious antinociceptive
effect in CCI-submitted mice. In accordance with previous data
showing that 2-DMPI exhibited a potency ﬁve-fold higher than
moclobemide at inhibiting in vitro MAO-A activity (Villarinho et al.,
2012a), 2-DMPI was approximately four times more potent than
moclobemide at reducing the hyperalgesia induced by CCI. IndicatingTable 1
Effects of moclobemide (300 μmol/kg, s.c., 2 h before test), 2-DMPI (300 μmol/kg, s.c.,
2 h before test) or pregabalin (100 μmol/kg, s.c., 1 h before test) treatment on latency
for the ﬁrst fall (s) and total number of falls in the rota-rod test in mice.
Latency (s) Fall number
Vehiclea 139 (28–240) 2 (0–3)
Moclobemide 142 (55–240) 1 (0–2)
2-DMPI 149 (28–240) 1 (0–3)
Salineb 133 (72–185) 2 (1–3)
Pregabalin 129 (58–240) 2 (0–3)
Data are expressed as medians (interquartile ranges) of 6 animals per group.
a Injected 2 h before test.
b Injected 1 h before test.the inhibition of MAO-A when administered in vivo, previous studies
demonstrated that 2-DMPI and moclobemide presented antidepressant-
like effect and increased central monoamine levels in doses where they
possess antinociceptive effect (Da Prada et al., 1989; Miura et al., 1996;
Villarinho et al., 2012a). Moreover, we also tested the effect of pregabalin,
aﬁrst line drug for the treatment of neuropathic pain (Gajraj, 2007), in the
CCI-induced hyperalgesia. Similar to reversible MAO-A inhibitors,
pregabalin also exhibited an efﬁcacious antihyperalgesic action at a dose
(100 μmol/kg) that caused no change on motor coordination function.
However, the antinociceptive effect of moclobemide and 2-DMPI was
more long-lasting than that produced by pregabalin.
Consistent with our results, there is increasing evidence supporting
the analgesic potential of MAO-A inhibitors (Apaydin et al., 2001;
Bianchi et al., 1992; Coquoz et al., 1993; Dina et al., 2008; Pirildar et
al., 2003; Schreiber et al., 1998). The selective and irreversible MAO-A
inhibitor clorgyline produced an antiallodynic effect in a model of alco-
holic neuropathy in rats (Dina et al., 2008). Moreover, Apaydin et al.
(2001) demonstrated in a preliminary report that moclobemide atten-
uated mechanical hyperalgesia in rats submitted to mild sciatic nerve
compression. However, the authors did not investigate the mechanism
underlying this antinociceptive effect or possible changes in MAO-A ac-
tivity in this neuropathic pain model.
To explore whether chronic constriction of the sciatic nerve could
induce any alteration of MAO-A in speciﬁc central nervous system
structures (lumbar spinal cord, striatumand cerebral cortex) implicated
in pain modulation (Millan, 2002), MAO-A activity was measured in
sham-operated and CCI-submitted mice. The activity of MAO-A in the
lumbar spinal cord was shown to be increased in mice subjected to
CCI. To our knowledge, this is the ﬁrst study showing changes in the
MAO-A activity in the lumbar spinal cord of neuropathic mice,
suggesting a possible involvement of this enzyme in the pathophysio-
logical mechanisms of CCI neuropathic pain model.
Chronic constriction of the sciatic nerve could lead to a decrease in
the availability of the neurotransmitter serotonin, which plays a critical
role in descending pain modulation pathways (Millan, 2002), by in-
creasing the MAO-A activity in the lumbar spinal cord. Previous studies
have demonstrated that the serotonin level is markedly decreased in
some central nervous system structures involved in pain pathways,
including the cerebral cortex, the ventrobasal thalamus, the raphe
magnus nucleus, and the spinal cord in various neuropathic pain
models (Goettl et al., 2002; Hains et al., 2002; Liu et al., 2010; Sandrini
et al., 1997; Sounvoravong et al., 2004). Furthermore, Vogel et al. (2003)
showed a decrease in serotonin levels in the lumbar spinal cord of
CCI-submitted mice. Because spinal levels of serotonin are important for
the antinociceptive effect of many drugs (Alloui et al., 2002; Arcioni et
al., 2002; Bilge et al., 2012; Kawamata et al., 2002; Kawamura et al.,
1998; Pelissier et al., 1996), 2-DMPI and moclobemide could be exerting
their analgesic effect by inhibiting MAO-A activity and consequently
increasing the levels of serotonin in the spinal cord.
Although descending serotonergic pathways have been implicated
in both inhibitory and facilitatorymodulation of spinal neuronal activity
(Millan, 2002), several studies have demonstrated that the activa-
tion of 5-HT3 receptors in the spinal cord has an antinociceptive effect
(Alhaider et al., 1991; Bardin et al., 2000; Giordano, 1991). In the
present study, micewere intrathecally injected with the 5-HT3 receptor
antagonist ondansetron to evaluate if the antinociceptive effects of the
reversible MAO-A inhibitors 2-DMPI and moclobemide were mediated
by the spinal serotonergic system. The antinociceptive effects of 2-DMPI
and moclobemide were largely reversed by the intrathecal injection of
ondansetron. In accordancewith our results, Nakajima et al. (2012) dem-
onstrated that the intrathecal treatment with ondansetron abolished the
antihyperalgesic effect of the selective serotonin reuptake inhibitor
paroxetine in a neuropathic pain model in rats. Moreover, ondansetron
did not change the CCI-induced mechanical hyperalgesia in mice treated
with vehicle. This result may be expected because ondansetron, as a pure
antagonist, would only produce effect in CCI-induced hyperalgesia with
141J.G. Villarinho et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 44 (2013) 136–142an increased endogenous agonist (5-HT) tone, which probably did not
occur in spinal cord of CCI-submitted mice, since MAO-A activity was
augmented.
Furthermore, some studies have shown that the intrathecal admin-
istration of the selective 5-HT3 receptor agonist chlorophenylbiguanide
(m-CPBG) produced antiallodynic effects in neuropathic rats, which
appear to be mediated by γ-amino butyric acid (GABA)ergic inhibitory
synaptic transmission (Hayashida et al., 2012; Okazaki et al., 2008).
Moreover, previous studies showed that the 5-HT3A receptor subunit
is present in GABAergic and enkephalinergic neurons (Huang et al.,
2008) and that the activation of 5-HT3 receptors evokes GABA release
(Kawamata et al., 2003) in the spinal dorsal horn, suggesting that
5-HT3 receptor activationunderlies the antinociceptive effect of serotonin
at the spinal cord level. Therefore, by increasing the spinal levels of sero-
tonin, the reversible MAO-A inhibitors 2-DMPI and moclobemide could
activate 5-HT3 receptors on inhibitory interneurons in the spinal dorsal
horn, which can inhibit pain by increasing the release of inhibitory trans-
mitters. Despite our results suggest that the antinociceptive effect of re-
versible MAO-A inhibitors was mediated by 5-TH3 receptors, we cannot
exclude the possible involvement of other serotonergic receptors, such
as 5-HT1A, 5-HT4 and 5-HT7, which may also be involved in nociceptive
processing (Berrocoso et al., 2007; Brenchat et al., 2012; Jeong et al.,
2004).
Finally, the highest tested dose (300 μmol/kg) of 2-DMPI and
moclobemide did not affect the paw withdrawal threshold in
sham-operatedmice at any timemeasured compared with the baseline
withdrawal threshold (measured before surgery procedure), indicating
that these reversible MAO-A inhibitors might be effective in neuropathic
pain states, without affecting physiological protective pain. Furthermore,
moclobemide and 2-DMPI, at a dose with antinociceptive effect
(300 μmol/kg), caused no change onmotor coordination function, elimi-
nating a possible false positive antinociceptive effect owing to a motor
impairment. In a previous study (Villarinho et al., 2012a), 2-DMPI
presented fewer adverse effects than moclobemide because the latter
caused a deﬁcit in the motor activity of mice at the highest dose tested
(1000 μmol/kg). Thus, 2-DMPI may be a prototype for the development
of new and safer reversible inhibitors of MAO-A with a potential thera-
peutic value for the treatment of neuropathic pain conditions.5. Conclusion
Taken together, the results of the present study showed that
2-DMPI and moclobemide presented an antinociceptive effect in the
CCI neuropathic pain model in mice, which appears to be related to
the activation of spinal serotonergic 5-HT3 receptors. Furthermore,
CCI-submitted mice presented an increase in MAO-A activity in the
lumbar spinal cord, suggesting a possible involvement of this enzyme in
the mechanism of neuropathic pain and a potential utility for reversible
MAO-A inhibitors in the development of new therapeutic approaches.Acknowledgments
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